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Abstract
Background: To compare vancomycin pharmacokinetic parameters in patients with and without neutropenia.
Methods: Patients $18 years admitted on general wards were included. Routinely vancomycin trough and peak plasma
concentrations were measured with a fluorescence polarization immunoassay. Pharmacokinetic parameters of individual
patients were determined with maximum a posterior Bayesian estimation (MW Pharm 3.60). Neutropenia was defined as
neutrophils ,0.56109 cells/L.
Principal Findings: A total of 171 patients were included. Patients with neutropenia (n = 56) had higher clearance of
vancomycin (CLva), 67 (626) mL/min, compared to patients without neutropenia (n = 115), CLva 50 (622) mL/min (p,
0.001). No significant difference was found in serum creatinine and vancomycin volume of distribution. Neutropenia was
positively associated with CLva, independently of relevant co-variables (B: 12.122, 95%CI: 1.095 to 23.149, p = 0.031). On
average patients with neutropenia needed 33% higher doses of vancomycin to attain adequate exposure, i.e. AUC24$
400 mg6h/L. Furthermore, 15 initially neutropenic patients in our study group received vancomycin for a second
administration period. Ten patients received the second administration period during another neutropenic period and 5
patients during a non-neutropenic phase. All 5 patients with vancomycin during both neutropenic and non-neutropenic
phase had higher CLva (91 (626) mL/min) during the neutropenic period and lower CLva (45 (610) mL/min) during the
non-neutropenic phase (p = 0.009).
Conclusion: This study shows that most patients with neutropenia have augmented CLva. In a small group of patients that
received vancomycin during two episodes, the augmented CLva seems to be reversible in the non-neutropenic period. Our
data indicate that it is important to increase the daily dose with one third in patients with neutropenia (from 15 mg/kg
twice daily to 13 mg/kg three times daily). Frequent performance of therapeutic drug monitoring in patients with
neutropenia may prevent both therapy failure due to low AUCs and overcomes toxicity due to high vancomycin trough
concentrations during recovery from neutropenia.
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Introduction
Mortality from infections after cytostatic conditioning regimens
in hematologic neutropenic patients requiring hematopoietic cell
transplantation is high [1]. Bacterial infections are common during
neutropenic phases and antibiotics, such as vancomycin, are often
required [2]. In a recent surveillance study, Gram positive
organisms are the most common cause of bacteremia in
hematology patients, i.e. coagulase negative staphylococci (36%),
followed by, Streptococci (11%), S. aureus (8%) and Enterococci
(4%) [3]. Antibiotics should be started within 1 hour in patients
with severe sepsis. However, adequate dosing of vancomycin can
be difficult. Augmented clearance has been increasingly described
in critically ill patients at the Intensive Care Unit (ICU) [4–6].
Changes in volume of distribution (Vd), changes in renal function
and severe hypoalbuminemia are often present, influencing
vancomycin plasma concentrations. Augmented clearance of
vancomycin leads to lower vancomycin plasma concentrations,
decreased 24-hour area under the curve (AUC24) and leads to
diminished clinical outcome [6]. Augmented clearance of vanco-
mycin in patients with hematological malignancies has been
reported, but the augmented clearance was not associated with
population specific covariables [7]. In another study low
teicoplanin trough concentrations in neutropenic patients were
reported, suggesting augmented clearance of teicoplanin in
neutropenic patients [8]. In addition, elevated clearance of
piperacillin and ceftazidime has also been noticed in patients with
febrile neutropenia [9,10]. The mechanism of augmented
clearance of antibiotics is not completely understood and is poorly
investigated in patients with hematologic malignancies or in
patients with neutropenia. The aim of this study is to compare
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vancomycin pharmacokinetic parameters in patients with and
without neutropenia at non-ICUs in a University Hospital.
Methods
Materials and Methods
Study group. In this observational study patients were
prospectively followed. Patients older than 18 years treated with
vancomycin intravenously (iv) and hospitalized at the Maastricht
University Medical Center (MUMC), a 715 bed university
hospital, were included from May 2011 until July 2013. Patients
were excluded when admitted at the ICU or when insufficient data
was collected. Vancomycin was started at the discretion of the
attending physician, either empirically or as therapy for bacteria
susceptible to vancomycin. Dose individualization was applied
since an initial loading dose of 15 mg/kg was followed by dose
adjustment based on therapeutic drug monitoring (TDM) and
renal function. Demographic and clinical data, such as age,
gender, weight, temperature, co-medication, length of hospital
stay, time of administration of vancomycin and laboratory
parameters, such as, serum creatinine (Jaffe´ method), and
leucocytes were retrieved from the electronic patient file (SAP,
the Netherlands). Neutropenia was defined as ,0.56109 cells/L.
Creatinine clearance (CLcr) was calculated with the Cockcroft and
Gault formula [(140 - age in years) 6 weight in kg]/[serum
creatinine in mmol6 factor] using total bodyweight [11].
Ethics statement. This study was conducted according to
the principles expressed in the Declaration of Helsinki. This study
was registered at the Dutch Trial Register (NTR 1725). The
Medical Ethical Committee of the Maastricht University Medical
Center (MEC 08-4-063) approved this study and waived the
necessity to obtain informed consent from participants because of
the observational design. Electronic health records were anon-
ymized prior to use.
Measurement of vancomycin. Vancomycin plasma con-
centrations were measured as standard clinical care with a
fluorescence polarization immune assay using of Cobas Integra
800 system (Roche Diagnostics). The calibration curve ranged
from 2.0 to 80 mg/L. The accuracy and coefficients of variation
(CV) of the controls (6.9, 17.7 and 31.0 mg/L) were within 90%–
110% and ,3.3%, respectively. Patients with at least two plasma
samples available, drawn in such a manner to ensure calculations
of vancomycin clearance (CLva) were included. Blood samples
were collected at least one hour after the end of infusion and
trough levels were obtained just before the next dose.
PK-analysis. Pharmacokinetic parameters (CLva, Vd) of
vancomycin in individual patients were calculated with maximum a
posterior (MAP) Bayesian estimation computer program (MW/
Pharm 3.60, Mediware, the Netherlands). Bayesian priors from a two
compartment open pharmacokinetic model based on previous studies,
were applied: V1 0.2160.04 L/kg, kelm 0.014360.0029 h
21, kelr =
kslope 6 CLcr (mL/min), 0.0032760.00109 h
21/mL/min, k12
1.1260.28 h21, and k21 0.4860.12 h
21 [12,13], where V1 is
volume of distribution central compartment (L/kg); kelm, metabolic
elimination rate constant (h21); kslope, renal elimination rate
constant (h21/mL/min); kelr, renal elimination rate constant
(h21); k12 (h
21), rate constant from the 1st to the 2nd compartment;
and k21(h
21), vice versa. The elimination rate constant kel = kelm +
kelr = kelm + (kslope6CLcr) [14]. WithMAP Bayesian estimation all
patient characteristics and measured vancomycin concentrations
are fitted on an existing population model. With at least two
concentrations per patient individual pharmacokinetic parameters
can be adequately derived with MAP Bayesian estimation [15,16].
With these individual pharmacokinetic parameters, dosing simula-
tions were made to adjust the dose individually; this MAP Bayesian
Figure 1. Flow of the 171 included patients with regard to hematology, neutropenia and two vancomycin administration periods.
doi:10.1371/journal.pone.0112008.g001
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estimation is a standard procedure in institutes which provide TDM
service.
The AUC24 in steady-state was calculated with the formula: 24-
hour dose/CLva.
Analysis of patients with and without
neutropenia. Pharmacokinetic, clinical and demographic pa-
rameters were compared in patients with and without neutropenia
in all patients and in patients with hematological malignancies.
Furthermore, pharmacokinetic parameters of two vancomycin
administration periods within the same patients were compared.
Both patients with two vancomycin administrations during two
different neutropenia periods and patients with two vancomycin
administrations during one neutropenia period and one period
without neutropenia were compared.
Statistical analysis. Normal distribution was evaluated for
metric variables by means of the Shapiro-Wilk test and presented
as mean (6SD). If not, median and ranges were given. Categorical
variables are presented as frequencies and percentages. Metric and
categorical variables were evaluated between patients with and
without neutropenia using the Student t-test or non-parametric
test (Kruskal Wallis), respectively.
First, the influence of co-variables on CLva was determined in
univariable (Pearson) analysis. Subsequently, only the significant
co-variables in the univariable analyses were included in the
multivariable analysis, after checking the assumptions. The Enter
method was used in the multivariable linear regression. CLcr is
estimated with the C&G formula which includes serum creatinine,
age, weight and gender [11]. To avoid multicollinearity, serum
creatinine, age, weight and gender were left out of the
multivariable model. Data analysis was done with IBM SPSS-pc
version 20.0. A p-value of ,0.05 was considered to be statistically
significant.
Results
Study group
The mean age was 59 (614) years and 61% were male. Patients
were admitted on different general wards; hematology ward (40%,
68/171), surgery ward (19%, 32/171), internal ward (11%, 19/
171), neurosurgery ward (11%, 18/171), orthopedic ward (10%,
17/171), cardiac (9%, 15/171) and eye ward (1%, 2/171). The
majority of patients had sepsis (46%, 79/171), implant infection
(16%, 27/171) or abdominal infection (15%, 25/171). A total of
171 patients with a mean (6SD) of 6 (63) vancomycin plasma
concentrations were included.
Pharmacokinetics analysis
The mean dose (6SD) of vancomycin per 24 hours was 1683
(6759) mg, with a mean Vd of 58 (630) L and AUC24 of 502
(697) mg6h/L. The mean (6SD) trough concentration in steady
state (SS) was 13 (64) mg/L, CmeanSS was 21 (64) mg/L, peak
concentration in SS was 49 (614) mg/L, CLva was 56 (625) mL/
min and serum creatinine was 89 (668) mmol/L.
Analysis of patients with and without neutropenia
Sixty eight patients had a hematological malignancy and 56
patients were neutropenic, Figure 1. Neutropenic patients (n = 56)
had higher CLva, 67 (626) mL/min, compared to non-
neutropenic patients (n = 115), CLva 50 (622) mL/min (p,
0.001). No significant difference in serum creatinine and Vd was
found, Table 1 and Figure 2. Forty eight percent (27/56) of the
neutropenic patients had CLva .70 mL/min, compared to 21%
(24/115) without neutropenia. Of the 68 patients with a
hematological malignancy, 55 patients were neutropenic and 13
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were not neutropenic. Within the hematologic malignancy
patients, neutropenic patients had higher CLva, than non-
neutropenic patients, Table 1 and Figure 2. Physicians used
TDM and adjusted vancomycin dosing as shown by the mean
dose of vancomycin in patients with neutropenia of 2017 (6720)
mg compared to 1521 (6727) mg in patients without neutropenia,
p,0.001. On average, among patients with neutropenia the daily
vancomycin dose was 33% (500 mg/day) higher to achieve the
same AUC24 (Table 1). Patients with sepsis (n = 79) had higher
CLva and were younger than patients without sepsis (n = 92). Vd
and CLcr were not different, Table 2. Neutropenic patients with
sepsis (n = 47) seemed to have slightly higher CLva of 69 (627)
mL/min than neutropenic patients without sepsis (n = 9) CLva 60
(622) mL/min, p= 0.269. Both neutropenic patients with sepsis
and without sepsis had higher CLva than non-neutropenic
patients.
Of the 171 patients, 15 neutropenic patients received a second
period of vancomycin, of which 5 patients received vancomycin
during both an neutropenic and non neutropenic period. Ten
patients received two vancomycin episodes during neutropenic
periods. However, 3 patients developed kidney failure and were
taken out. Leaving 7 patients with two vancomycin periods during
neutropenia, Figure 1. Therefore, the data of 7 patients with two
neutropenic periods and 5 patients with both a neutropenic and
non-neutropenic period could be compared. The median (range)
of time between the two vancomycin administrations was 30 (20–
108) days for these 7 patients and 21 (14–136) days for the 5
patients with both a neutropenic and non neutropenic period. For
the 7 patients with vancomycin administrations in two neutropenic
periods, the CLva remained similar: 77 (630) to 70 (623) mL/
min (p = 0.748), as did the serum creatinine 68 (613) to 66 (611)
mmol/L (p= 0.701) and CLcr 120 (641) to 117 (635) mL/min
(p = 0.848). The 5 patients with vancomycin administrations in
both a neutropenic and non-neutropenic period had a statistically
significantly higher CLva, 91 (626) mL/min, during the
neutropenic phase compared to CLva, 45 (610) mL/min during
the non-neutropenic phase (p = 0.009). Serum creatinine, 65 (610)
and 69 (611) mmol/L (p = 0.462) and CLcr, 141 (670) and 113
(648) mL/min during the neutropenic and non-neutropenic
periods, respectively, were not significantly different (p = 0.402),
Figure 3 and neither was the Vd was 74 (624) L during
neutropenic and 51 (610) L during non-neutropenic phase
(p = 0.175).
CLcr, neutropenia, hematologic malignancy and sepsis were
correlated with CLva in the univariable analysis, Table 3. In the
multivariable analysis, CLva was positively associated with CLcr
(B: 0.205, 95%CI: 0.164–0.245, p,0.001) and neutropenia (B:
12.122, 95%CI: 1.095 to 23.149, p = 0.031), Table 3.
Discussion
Our study shows that higher doses of vancomycin are needed
during neutropenic periods to achieve vancomycin target AUC24
and target trough concentrations. The augmented clearance of
vancomycin in neutropenic patients seems reversible. Augmented
clearance of vancomycin cannot be predicted with the estimated
CLcr, as serum creatinine and estimated CLcr in our study are not
significantly different in neutropenic and non-neutropenic pa-
tients. Moreover, the estimated CLcr is not reliable above 125
mmol/L and shows a poor agreement with measured CLcr in urine
in critically ill patients displaying augmented clearance of
creatinine [17,18]. Our Bayesian calculated CLva is in line with
the population estimated CLva in patients with hematological
malignancies in the simulations by Buelga et al. [7]. However, our
routine patient care observations demonstrate that augmented
clearance is associated with neutropenia rather than hematological
malignancy and sepsis. In the multivariable analysis neutropenia
(yes/no) was positively associated with CLva, independently of the
Figure 2. Boxplot for vancomycin clearance (CLva) in patients with and without neutropenia in all patients (A) and in patients with
haematological malignancy (B). Lower and higher boundary of the box indicates 25th and 75th percentile, respectively, the line within the box
marks the median, the whiskers above and below the box indicate the 90th and 10th percentiles and the open circles indicate outside the 90th and
10th percentiles.
doi:10.1371/journal.pone.0112008.g002
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Table 2. Mean (6SD) for Age, CLcr, CLva, Vd, Creatinine for patients with sepsis and without sepsis.
N Age years CLva mL/min Vd L CLcr mL/min Creatinine mmol/L
Sepsis 79 56 (613) 60 (627) 57 (626) 108 (656) 84 (638)
No sepsis 92 61 (614) 52 (623) 58 (633) 110 (683) 96 (671)
p 0.017 0.048 0.639 0.535 0.894
CLva: vancomycin clearance.
CLcr: creatinine clearance calculated from serum creatinine with Cockcroft and Gault [11].
Vd: volume of distribution.
doi:10.1371/journal.pone.0112008.t002
Figure 3. A. Vancomycin clearance (CLva) and B. serum creatinine of 5 patients (number 1–5) during both a neutropenic and a non-
neutropenic phase and C. CLva and D. serum creatinine of 7 patients (number 1–7) during two neutropenic phases.
doi:10.1371/journal.pone.0112008.g003
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other co-variables. Although, our group of patients that received a
second administration of vancomycin is small, the augmented
clearance of vancomycin seems to be temporarily and reversible,
as the CLva returned to normal during the non-neutropenic
phase. The mechanism of augmented clearance is not completely
clarified; most likely more than one factor is involved in developing
augmented clearance. Young age, increased blood flow to the
kidneys, genetic factors and other medication has been proposed
to influence the CLva [5,6]. Neutropenia might be added to this
list. Most likely augmented clearance also influences other renally
cleared antibiotics [9,10]. Therefore, TDM of these antibiotics or/
and at least one 24-hour creatinine measurement in urine to
determine the most accurate CLcr at the ICU is recommended
[5,19,20]. Our data suggest that this recommendation may be
extended to neutropenic patients.
Our study has a couple of limitations. Firstly, our study is a real-
life observational study and we assumed the TDM protocol was
strictly followed by clinicians, especially the timing of peak
concentrations. Secondly, our group of patients with a second
vancomycin administration was rather small to prove the
demonstrated tendency of reversibility of elevated CLva, at the
moment when patients are recovering from neutropenia. Further
research is needed to fully understand the complex pharmacoki-
netics of vancomycin and other antibiotics in patients with
neutropenia. A prospective study may elucidate which other
factors are involved in augmented CLva, but such a study would
need a multicenter design and inclusion of many patients. Until,
we fully understand augmented clearance, we suggest to increase
the initial daily dose of vancomycin with 33% (13 mg/kg three
times daily) in patients with neutropenia and to perform TDM
after the first vancomycin dose in patients to prevent low plasma
concentrations of vancomycin and consequently reduced efficacy.
When patients are recovering from neutropenia, TDM is again
necessary to adjust the vancomycin dose to prevent toxicity due to
high vancomycin exposure.
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